Charles River Laboratories International (CRL) to Release Quarterly Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) is projected to post its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of $2.33 per share and revenue of $986.98 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:30 AM ET.

Charles River Laboratories International Price Performance

NYSE CRL opened at $161.15 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The company has a market cap of $7.93 billion, a PE ratio of -103.30, a price-to-earnings-growth ratio of 4.88 and a beta of 1.63. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $228.88. The firm’s 50-day simple moving average is $203.27 and its two-hundred day simple moving average is $179.70.

Institutional Trading of Charles River Laboratories International

Institutional investors and hedge funds have recently modified their holdings of the business. Victory Capital Management Inc. grew its holdings in shares of Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after purchasing an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after purchasing an additional 575,039 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in Charles River Laboratories International by 722.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock worth $65,885,000 after buying an additional 381,432 shares in the last quarter. Alyeska Investment Group L.P. grew its stake in Charles River Laboratories International by 120.7% in the 4th quarter. Alyeska Investment Group L.P. now owns 644,726 shares of the medical research company’s stock worth $128,610,000 after buying an additional 352,549 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Charles River Laboratories International by 27.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock worth $287,703,000 after buying an additional 311,319 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Robert W. Baird set a $224.00 price target on Charles River Laboratories International in a report on Friday, January 9th. Evercore lifted their price target on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Finally, TD Cowen reissued a “buy” rating on shares of Charles River Laboratories International in a report on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $209.46.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.